After the FDA closing the Michigan Abbott plant, a shortage of infant formula was created. The FDA provided an update on steps that will lead to millions of cans of additional infant and specialty formula being available to US consumers. The FDA, exercising enforcement discretion for importing certain infant formula, allows Kendal Nutricare currently has over 40,000 cans in stock, for immediate sending to the US as quickly as possible. A new process in which the FDA would not object to importing certain infant formula products intended for a foreign market or distribution in the US of products manufactured here for export to foreign countries. The FDA remains in further discussions with manufacturers and suppliers regarding additional supplies. The FDA is announcing that it is not objecting to releasing about 300,000 cans of EleCare amino acid-based infant formula previously produced at Abbott Nutrition’s Sturgis, Michigan, facility. The FDA also announced that EleCare will be the first formula produced at the Sturgis facility when it restarts production. The FDA also monitors online marketplaces for fraudulent products and works with major online retailers to remove violative and harmful products offered for sale on their sites. @ https://www.fda.gov/news-events/press-announcements/fda-flexibilities-yield-millions-cans-additional-infant-formula-coming-months-increase-supply?utm_medium=email&utm_source=govdelivery
FDA is working on getting millions of cans of infant formula to the US in coming Months
FDA Flexibilities to Yield Millions of Cans of Additional Infant Formula in Coming Months to Increase Supply Available to U.S. Consumers
FDA is providing an update on steps it has taken that will lead to millions of cans of additional infant and specialty formula being available in the U.S.